"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
| Descriptor ID |
D000726
|
| MeSH Number(s) |
D06.347.065 D27.505.696.399.450.065
|
| Concept/Terms |
Anti-Androgen Effect- Anti-Androgen Effect
- Anti Androgen Effect
- Effect, Anti-Androgen
- Antiandrogen Effect
- Effect, Antiandrogen
- Antiandrogen Effects
- Effects, Antiandrogen
- Anti-Androgen Effects
- Anti Androgen Effects
- Effects, Anti-Androgen
|
Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".
This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 3 | 4 |
| 2010 | 2 | 4 | 6 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 2 | 6 |
| 2014 | 4 | 3 | 7 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 8 | 1 | 9 |
| 2018 | 4 | 3 | 7 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 1 | 9 | 10 |
| 2022 | 1 | 7 | 8 |
| 2023 | 2 | 13 | 15 |
| 2024 | 4 | 1 | 5 |
| 2025 | 3 | 3 | 6 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.
-
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026 Aug 29; 408(10557):793-807.
-
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. Lancet. 2026 03 14; 407(10533):1059-1071.
-
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial. Clin Cancer Res. 2026 Feb 04; 32(3):479-488.
-
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol. 2026 May; 89(5):396-403.
-
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2026 May; 44(13):1198-1205.
-
Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment. PLoS One. 2025; 20(12):e0337828.
-
The comeback of orchiectomy in advanced prostate cancer- is that feasible? Urol Oncol. 2025 Dec; 43(12):714-720.
-
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115). Int J Radiat Oncol Biol Phys. 2025 12 01; 123(5):1247-1258.
-
The Evolving Management of Radiorecurrent Prostate Cancer. Semin Radiat Oncol. 2025 Jul; 35(3):450-462.
-
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol. 2025 Sep; 88(3):277-290.